

Review

# Unravelling the Fate of Coronary Artery Disease in Patients Undergoing Valve Replacement for Severe Aortic Valve Stenosis

Lennert Minten<sup>1,2,\*</sup>, Johan Bennett<sup>1,2</sup>, Keir McCutcheon<sup>1</sup>, Christophe Dubois<sup>1,2</sup><sup>1</sup>Department of Cardiovascular Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium<sup>2</sup>Department of Cardiovascular Medicine, University Hospitals Leuven (UZLeuven), 3000 Leuven, Belgium\*Correspondence: [Lennert.minten@gmail.com](mailto:Lennert.minten@gmail.com) (Lennert Minten)

Academic Editors: Elmar W. Kuhn and Matti Adam

Submitted: 17 December 2022 Revised: 6 January 2023 Accepted: 10 January 2023 Published: 23 February 2023

## Abstract

Severe aortic valve stenosis is the most frequent valve pathology in the western world and approximately 50% of these patients have concomitant coronary artery disease (CAD). Revascularization of proximal obstructive CAD in patients undergoing surgical aortic valve replacement (SAVR) is common practice considered appropriate. However, the management of patients with CAD undergoing transcatheter aortic valve implantation (TAVI) is more controversial. Nevertheless, performing percutaneous coronary intervention (PCI) of significant (>70%) proximal coronary lesions is a widely adopted strategy, but robust supporting scientific evidence is missing. Some studies suggest that complex CAD with incomplete revascularization negatively impacts outcomes post-TAVI. As increasingly younger patients are undergoing TAVI, optimizing the long-term outcomes will become more important. Although PCI in TAVI patients is safe, no benefit on outcomes has been demonstrated, possibly due to an inadequate selection of prognostically important lesions for revascularization. A possible solution might be the use of coronary physiological indices, but these have their own limitations and more data is needed to support widespread adoption. In this review we provide an overview of current evidence on the outcomes after aortic valve replacement (AVR) and the evidence regarding revascularization in this population.

**Keywords:** coronary artery disease; aortic valve stenosis; percutaneous coronary intervention; transcatheter aortic valve implantation

## 1. Introduction

Coronary artery disease (CAD) and aortic valve stenosis (AS) have common risk factors and a shared pathogenesis, and therefore frequently co-exist in clinical practice [1]. In patients receiving surgical aortic valve replacement (SAVR), 40–65% of patients undergo concomitant coronary artery bypass grafting (CABG) and this percentage increases with age [2,3]. In patients considered for transcatheter aortic valve implantation (TAVI), approximately 50% have obstructive CAD and half of these have multivessel disease with a reported mean Syntax score (SS) of 14 [4–6]. Both CAD and AS can present with dyspnea and angina, and their relative contribution to the complaints of the patient is often unclear [7]. Finally, AS can cause myocardial ischemia on its own, further complicating the assessment of CAD and the need for revascularization [8]. Significant CAD has been defined in the American guidelines as a minimal 70% reduction in diameter in a major coronary artery (50% in the left main coronary artery) and/or physiologically significance [9]. This guideline considers it is reasonable to revascularize these significant lesions both in patients undergoing SAVR (with concomitant CABG) or TAVI (with percutaneous coronary intervention (PCI) before TAVI) irrespective of anginal complaints, although only with a level C evidence. According to the latest European guidelines, in patients undergoing SAVR, CABG of lesions >70% stenosis is recommended (50% for left main) and CABG could be considered in lesions

>50% stenosis [10]. Both recommendations are equally supported by a level C evidence. In patients undergoing TAVI, PCI should be considered in coronary artery diameter stenosis >70% in proximal segments, with again a level C evidence [10]. These weak recommendations underscore the level of uncertainty regarding the best way to assess and select CAD for potential treatment in this context. A strategy using coronary physiology indices has been proposed to improve lesion selection for revascularization and clinical outcomes, but such approach needs further validation in patients with severe AS [11,12]. In this focused review, we describe the impact of CAD on clinical outcomes in patients undergoing aortic valve replacement (AVR) for AS, we depict the available methods to assess lesion severity and provide an overview of current available evidence on revascularization.

## 2. Impact of CAD on Outcomes

### 2.1 Patients Undergoing SAVR

Current evidence suggests that patients with CAD and AS have worse clinical outcomes after AVR. A large systematic review showed that patients with CAD had a higher risk of early mortality after valve replacement [13]. Another retrospective analysis showed that omitting revascularization in these patients is an independent predictor for early mortality [14]. Moreover, Cox regression analysis identified CAD as a determinant of late mortality after hospital discharge.



## 2.2 Patients Undergoing TAVI

In contrast with SAVR, observational studies assessing the association of CAD and outcomes post-TAVI have provided heterogenic results. These studies show CAD to have either no, a partial (only severe/complex lesions) or a systematic negative prognostic effect on short term outcomes after TAVI. Even two large meta-analyses on this topic revealed conflicting results [6,15]. One showed that the presence of CAD did not affect 30-day outcomes after TAVI, but demonstrated a significant negative effect of CAD on survival one year after the procedure [15]. The other suggested that the presence of CAD did not impact on 30-day or one year mortality after TAVI [6]. However, the presence of severe CAD (defined by a SS >22) in this study did result in a higher one-year mortality after TAVI. Conflicting results in observational data may be explained by differences in the definition used (history of CAD vs coronary lesions at the time of TAVI), the absence of systematic assessment of lesion severity (angiography-guided or using coronary pressure indices) or the lack of objective scoring of anatomical complexity (e.g., SS). Moreover, when a SS was calculated, different cut-off points to define severe CAD appear to have been used. Hence, whether the presence of CAD is simply a marker of atherosclerosis burden and other co-morbidities or rather represents an independent risk factor for worse outcomes after TAVI, remains unclear at this point. Importantly, current meta-analyses merely reported outcomes until 1 year after TAVI. It is not unreasonable to expect that the presence of significant CAD might need more time to exert its impact on clinical outcomes, underscoring the need for long-term follow-up studies. Further emphasizing this point, a recent prospective study showed that CAD-complexity was an important determinant of long-term outcomes up to five years post-TAVI, with the most complex CAD-group having the worst prognosis [16].

## 3. Assessment of CAD in Patients with AS

### 3.1 Non-Invasive Assessment

There are multiple non-invasive methods for the assessment of the functional severity of CAD, by investigating the perfusion of the heart during stress. Stress testing is not routinely advised in current guidelines for valvular heart disease [9,10], mainly due to difficulties in interpreting the cause of hypoperfusion if it is seen, due to severe changes in coronary hemodynamics in AS, and due to some concerns about safety in this population. Nevertheless, a number of smaller studies have shown promising results. Perfusion cardiac magnetic resonance imaging (MRI) and positron emission tomographic (PET) have shown to be safe in AS patients, however their ability to identify flow limiting coronary lesions needs still to be validated [17–19]. Stress transthoracic echocardiography (TTE) in AS patients showed good specificity and moderate sensitivity to detect

>50% narrowing on invasive angiography [20]. Single-photon emission computed tomography (SPECT) myocardial perfusion imaging has found to be safe and predict significant CAD with a good sensitivity and specificity in patients with AS [21–24]. It also showed a good correlation with invasive coronary hemodynamic indices of CAD (Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR)) [25,26].

From an anatomical perspective, cardiac computed angiography (CTA) has successfully been used as an alternative to invasive coronary angiography (CA) during the pre-TAVI work-up [27]. Supporting this approach are numerous studies showing a very high sensitivity (89–99%) and negative predictive value (90–96%) compared with CA in this setting for the detection of significant coronary stenosis [28–34]. The disadvantage is a relative low specificity (37–91%) and positive predictive value (59–87%), although a broad range in values has been reported. Overall, CTA has a similar sensitivity but a lower specificity in severe AS patients when compared to patients without AS, probably in part due to the higher burden of coronary calcium in AS [35,36]. Combining coronary CTA analysis with valve sizing and assessment of vascular access during work-up might decrease the number of CA performed by up to 37%, and this percentage may further decrease as younger patients with a lower risk profile are being selected for TAVI [36]. Moreover, CTA may offer evaluation of the functional severity of lesions on top of anatomical information, with promising modalities such as CT-derived FFR. A study in AS patients showed that this tool was safe and feasible in this population, however with a moderate sensitivity (74%) and specificity (78%) and with a diagnostic accuracy of 77% compared to invasive FFR [37]. It is the view of the authors that CTA can be used during the pre-SAVR/TAVI workup in severe AS patients without angina, mainly to avoid unnecessary CA in relatively young low-risk patients with a low pre-probability of CAD. In patients with a very high coronary risk profile, history of CAD or active angina the performance of CA would remain standard practice.

### 3.2 Angiographic Anatomical Assessment

Studies assessing CAD in patients with severe AS have used a luminal narrowing of  $\geq 50\%$  [38–41] or  $\geq 70\%$  [42,43] during invasive CA to define significant disease. Visual assessment of lesion severity carries high inter- and intra-observer variability, and quantitative coronary angiography (QCA) may therefore be the preferred method [44]. However, there are some notable disadvantages: Firstly, there is no data showing that PCI guided by QCA for stable lesions in patients without AS offers any clinical benefit. Secondly, older studies have shown that coronary diameters might increase as AS progresses with a reversed effect after aortic valve replacement [45]. This might pose a problem in interpretation, as QCA before and after TAVI

may change. Lastly, severe coronary artery tortuosity and eccentric lesions with heavy calcification, both fairly common in the AS population, create problems for interpretation and decrease measurement accuracy (especially in 2D QCA) [46].

Building further on QCA imaging, quantitative flow ratio (QFR) is a technique integrating functional relevance of a coronary stenosis without the use of Adenosine or a pressure wire. During angiography the flow of contrast is analyzed and 3D QCA information is computed to estimate a pressure loss over a given lesion. In a recent study in patients with AS, QFR had a better diagnostic performance than angiography alone to assess FFR-based significance of a lesion [47]. However, diagnostic accuracy decreased considerably when the aortic valve area (AVA) was smaller than  $0.80 \text{ cm}^2$  and especially when it was smaller than  $0.60 \text{ cm}^2$ . This highlights the importance of altered hemodynamics in severe AS patients [48].

Alternatively, intravascular imaging using ultrasonography (IVUS) or optical coherence tomography, while providing more detailed anatomical information, has a limited role in the decision to revascularize in daily practice, and no studies are available in the AS population. However, for the treatment of left main coronary artery (LMCA) stenoses, a cut-off of  $>6.0 \text{ mm}^2$  for the minimal luminal area (MLA) measured with IVUS has been proposed for safely deferring revascularization of the LMCA and this cut-off was clinically validated in a non-AS population [49,50]. There are no immediate reasons to suspect this cut-off would be different in AS patients, however, population specific validation would be ideal before widespread adoption in clinical practice. Lower MLA cut-off values have been proposed and validated with FFR, however, caution should be used since these studies were performed only in Asian populations and a lower sensitivity and negative predictive value suggest significant LMCA stenosis might be missed using a lower cut-off [51,52].

Finally, from a more global perspective, anatomical scoring systems can be used to further describe the extent and complexity of CAD in the individual patient. Studies in AS patients have used the Duke Myocardial Jeopardy score [53] or the synergy between percutaneous coronary intervention with taxus and cardiac surgery – score (SYNTAX-score, SS) [54]. Some studies showed that patients with a high baseline SS or high residual SS had worse outcomes after TAVI in comparison with patients with less complex disease [16,44,55], indicating that these scores can potentially be used for risk stratification in patients with AS.

### 3.3 Pressure Wire Assessment

Angiographic assessment of luminal narrowing is a poor predictor of coronary hemodynamic physiological indices, such as coronary flow reserve (CFR), FFR, iFR and resting flow ratio (RFR). The blood flow through a coronary artery and its fractional decrease over a lesion are also de-

pendent on other physiological and anatomical factors besides luminal narrowing, such as the length of the lesion and microvascular function [56]. There is data supporting the use of these indices in stable CAD and the FAME-2 trial supports performing PCI in lesions with  $\text{FFR} < 0.8$  [12,57,58]. Therefore it is advised to support a decision to revascularize intermediate to severe stable lesions on a coronary hemodynamic assessment [59,60]. However, importantly, severe AS patients have been systematically excluded from these trials due to concerns related to the effect of valve stenosis and the resulting LV hypertrophy on the possibility of causing false negative or positive results. Nevertheless, the potential importance of these indices in this population has been illustrated in a retrospective study that suggested better outcomes for AS patients when comparing FFR-guided PCI with angiography-guided PCI [61]. Future studies will provide more data on the effect of valve replacement on coronary hemodynamics in patients with severe AS [62].

## 4. Revascularization

### 4.1 Revascularization in Surgical AVR

Although patients who undergo combined AVR with CABG have higher unadjusted mortality, this difference is no longer present after propensity matching [63,64]. Two retrospective studies showed that patients with significant AS and CAD undergoing SAVR with CABG had a significantly reduced early and late mortality when compared with SAVR alone [14,65]. Therefore concomitant revascularization of coronary lesions  $>70\%$  is currently advised, mostly in the form of CABG. However, a hybrid approach with PCI, could be considered as an alternative [66,67].

### 4.2 Revascularization in TAVI

Treatment of stable CAD with PCI in non-AS patients is controversial, and should potentially be viewed as mainly a symptomatic treatment, as several prospective randomized studies have not showed a clear prognostic benefit [68–70]. This becomes even more complex in the AS population, especially those who are elderly and frail. Revascularization with PCI pre-TAVI of every proximal coronary lesion with  $\geq 70\%$  narrowing is currently not supported by strong scientific evidence as documented in the latest guidelines [9,10]. However, as TAVI indications are expanding to younger and lower-risk patients, the correct assessment and treatment of CAD is key to optimize outcomes and quality of life of these patients. It has been shown that more complex CAD is associated with more myocardial injury (on the basis of serum troponins) post-TAVI [71,72]. Performing PCI of these lesions has shown to be safe as short-to-intermediate-term outcomes among patients with CAD that either did or did not undergo PCI have been found to be comparable in numerous observational studies (Table 1, Ref. [16,41,43,44,73–78]). Nevertheless, comparable clinical outcomes can also be seen as evidence that

**Table 1. Overview of studies investigating the impact of stable CAD and peri-TAVI revascularization on all-cause mortality after TAVI.**

Study	Design	Population	Follow-up time	Outcome	Result
Wenaweser <i>et al.</i> 2011 [73]	Single-centre prospective registry	197 TAVI vs 59 TAVR + PCI	2 years	All-cause Mortality	No difference ( $p = 0.96$ )
Abdel-Wahab <i>et al.</i> 2012 [41]	Single-centre retrospective registry	70 TAVI vs 55 TAVI + PCI	3 years	All-cause Mortality	No difference ( $p = 0.36$ )
Codner <i>et al.</i> 2013 [74]	Single-centre prospective registry	117 TAVI vs 36 TAVI + PCI	2 years	All-cause Mortality	No difference ( $p = 0.67$ )
Abramowitz <i>et al.</i> 2014 [43]	Single-centre prospective registry	105 TAVI (without CAD) vs 83 TAVI (with CAD) vs 61 TAVI + PCI	3 years	All-cause Mortality	No difference ( $p = 0.68$ )
Khawaja <i>et al.</i> 2015 [44]	Single-centre retrospective registry	68 TAVI (with CAD) vs 25 TAVI + PCI	1 year	All-cause Mortality	No difference ( $p = 0.918$ )
Snow <i>et al.</i> 2015 [75]	Multicentre prospective registry	2005 TAVI without historical PCI vs 363 TAVI with historical PCI vs 169 TAVI + hybrid PCI vs 169 TAVI + PCI	5 years	All-cause Mortality	No difference ( $p = 0.81$ )
Huczek <i>et al.</i> 2016 [76]	Multicentre retrospective registry	434 isolated TAVI (without CAD) vs 293 isolated TAVI (with CAD)	30 days	All-cause Mortality	No difference ( $p = 0.098$ )
Chakravarty <i>et al.</i> 2016 [77]	Multicentre retrospective registry	128 isolated TAVI vs 128 TAVR + LM PCI (1:1 case-control matched)	1 year	All-cause Mortality	No difference (HR: 1.09; 95% CI: 0.50–2.39; $p = 0.83$ )
Millan-Iturbe <i>et al.</i> 2017 [78]	Single-centre prospective registry	720 isolated TAVI (without CAD) vs 88 TAVI (with CAD) vs 136 TAVI + PCI	9 years	All-cause Mortality	No difference ( $p = 0.229$ )
Minten <i>et al.</i> 2022 [16]	Single-centre prospective study	239 isolated TAVI vs 107 TAVI + PCI	5 years	All-cause Mortality	No difference ( $p = 0.162$ )


CAD, coronary artery disease; 95% CI, 95% confidence interval; CR, complete revascularization; HR, hazard ratio; IR, incomplete revascularization; LM, left mainstem coronary artery; MACCE, major adverse cardiac and cerebrovascular events; PCI, Percutaneous coronary intervention; rSS, residual Syntax score; SS, Syntax-score; TAVI, Transcatheter aortic valve implantation.

revascularization of lesions  $\geq 70\%$  pre-TAVI is not absolute necessary. Ten percent of patients included in randomized studies comparing SAVR (+/- CABG) versus TAVI (+/- PCI) in low risk patients received revascularization [79–82]. These trials showed superiority or non-inferiority for the transcatheter arm for the combined end-point (stroke or death) at medium-term follow-up, indirectly supporting TAVI with PCI. Unfortunately, only one trial reported data on the subset of patients that underwent PCI or CABG (90 patients in total) [82]. A non-significant difference could be seen for the chance of rehospitalization/stroke/death between the groups favoring PCI (9.4% vs 12.1%, HR: 0.77; 95% CI: 0.20–2.98) [82]. Importantly, these randomized trials excluded patients with complex CAD (SS >22 or 32) and patients with significant left main disease.

In patients with stable CAD and ischemia without significant valvular disease, the ISCHEMIA trial confers limited to no influence on early invasive revascularization strategy on outcomes [70]. Nevertheless, AS patients with a very high burden or very complex CAD (represented by a high SS-score) may have better outcomes when revascular-

ized. Data to support this comes from observational studies that analyzed completeness of revascularization. Several studies have shown a correlation between incomplete revascularization (high residual SS) and worse clinical outcomes such as increased mortality or major adverse cardiac or cerebrovascular events (MACCE) supporting PCI in the peri-TAVI period [83–88]. However, other studies could not find an association between incomplete revascularization and clinical events [38,89–93]. Recently, two important papers regarding this topic were published. One prospective study with 5-year follow-up showed there was no benefit of (complete) revascularization for stable CAD in TAVI patients [16]. A large retrospective registry among TAVI patients with significant stable CAD showed no benefit of complete myocardial revascularization to reduce the risk of all cause death at 2 years [94]. Limitations in combining the results of these studies lie in differences in the definition of incomplete revascularization, follow-up times and comorbidities, and overall small patients numbers in the cohorts studied (Table 2, Ref. [16,38,83–94]).

## Severe Aortic Stenosis and Coronary Artery Disease



**Fig. 1. Central Figure with overview.**

To date, only one randomized clinical trial comparing TAVI with medical therapy vs TAVI with PCI in patients with severe AS and CAD has been performed [95]. CAD was defined as stenosis severity of >70%, 235 patients were enrolled and PCI was angiography-guided. At one-year there was no difference in the combined endpoint of rehospitalization or death between the medical and PCI group (44.0% vs 41.5% resp.,  $p = 0.067$ ). Furthermore, there were no differences in rates of acute kidney injury, myocardial infarction or stroke. Importantly, patients undergoing PCI presented significantly more all-cause bleeds (28.4% vs 44.5%,  $p = 0.02$ ) after one year. Of note, this trial did not reach its recruitment target (310 patients), non-inferiority of the primary end-point was not met and the study population had low rates of reported angina (70% of the patients reported Angina Canadian Cardiovascular Society class 0). An overview of the current evidence regarding the effect of CAD on outcomes after aortic valve replacement and the effect of revascularization can be found in Fig. 1.

Ideally, additional tools are needed to select patients benefiting most from PCI at the time of TAVI. Unfortunately, the invasive assessment of coronary hemodynamics by using indices such as FFR, iFR, and RFR cannot simply be extrapolated from patients with stand-alone stable CAD to a population with AS [48]. Severe AS induces dra-

matic changes in coronary physiology that are still incompletely understood. Moreover, it is unclear which index to use since it is expected that severe AS and valve replacement impact differently on these indices [96]. When looking at outcomes, one observational study compared patients who underwent angiography versus physiology-guided PCI before TAVR [61]. In this study, patients in whom the decision was based on physiological assessment had better survival free from MACCE at two years follow-up (HR: 0.40; 95% CI: 0.20–1.00,  $p = 0.035$ ). More studies to investigate the role of coronary physiological in AS are currently underway [62].

### 4.3 Timing of Revascularization

In case of acute cardiac symptoms (such as chest pain and dyspnea), raised troponin levels and ECG changes, the difficult differential between an acute coronary syndrome and acute decompensated AS should lead to the predominant cause of decompensation being treated first [97]. However, most decisions in this population are made in an elective setting.

For patients going to SAVR, CABG should be performed during the same procedure for obvious reasons. In contrast, patients receiving TAVI can undergo revascularization before, during or after valve implantation, and several considerations can be made in this respect.

**Table 2. Overview of studies investigating the impact of completeness of revascularization in the peri-TAVI period.**

Study	Design	Population	Follow-up time	Outcome	Result
Ussia <i>et al.</i> 2013 [89]	Multicentre prospective registry	92 TAVI + no PCI 88 TAVI + IR 95 TAVI + CR	1 year	All-cause mortality MACCE	No difference ( $p = 0.807$ ) No difference ( $p = 0.594$ )
Van Mieghem <i>et al.</i> 2013 [38]	Single-centre prospective study	124 TAVI + IR 139 TAVI + CR	1 year	All-cause mortality	No difference ( $p = 0.85$ )
Stefanini <i>et al.</i> 2014 [83]	Single-centre prospective registry	TAVI + PCI both groups: - 192 low residual SS (0–14) - 95 high residual SS (>14)	1 year	MACCE	High residual SS = higher risk (RR: 1.92; 95% CI: 1.02–3.61; $p = 0.042$ )
Kleczyński <i>et al.</i> 2016 [84]	Single-centre prospective registry	16 TAVI + IR 85 TAVI + CR	1 year	All-cause mortality	IR = higher mortality (HR: 10.86; 95% CI: 3.72–31.73; $p < 0.001$ )
Paradis <i>et al.</i> 2017 [90]	Multicentre retrospective registry	TAVI all groups: - 82 No CAD - 17 low residual SS (0–7) - 37 high rSS ( $\geq 8$ )	1 year	MACCE	No difference ( $p = 0.16$ )
Shamekhi <i>et al.</i> 2017 [85]	Single-centre prospective study	TAVI all groups: - 229 no CAD - 140 low residual SS (0–3) - 205 high residual SS (>3)	3 years	All-cause mortality	Univariate analysis: higher residual SS = increased mortality ( $p = 0.01$ ) Multivariate analysis: no significant effect of rSS
Witberg <i>et al.</i> 2017 [86]	Multicentre retrospective registry	TAVI all groups: - 817 no CAD - 331 low residual SS (0–8) - 122 high residual SS (>8)	5 years	All-cause mortality	High rSS = higher mortality (HR: 1.72; 95% CI: 1.051–2.814; $p = 0.031$ )
Li <i>et al.</i> 2019 [91]	Single-centre retrospective registry	TAVI + PCI in all groups: - 144 CR - 151 major IR - 29 minor IR	3 years	All-cause mortality MACCE	No difference ( $p = 0.40$ ) No difference ( $p = 0.18$ )
López Otero <i>et al.</i> 2019 [92]	Single-centre retrospective registry	TAVI + PCI in all groups: - 56 CR (rSS = 0) - 85 RCR (rSS = 1–7) - 46 IR (rSS $\geq 8$ )	3 years	All-cause mortality MACCE	No difference ( $p = 0.605$ ) No difference ( $p = 0.866$ )

**Table 2. Continued.**

Study	Design	Population	Follow-up time	Outcome	Result
Saia <i>et al.</i> 2019 [93]	Single-centre retrospective registry	TAVI + PCI in both groups: - 138 CR - 153 IR	5 years	Cardiovascular mortality	No difference ( $p = 0.25$ )
Landt <i>et al.</i> 2019 [87]	Single-centre retrospective registry	TAVI + PCI in both groups: - 129 CR (rSS = 0) - 78 IR (rSS >0)	1 year	All-cause mortality	CR = lower mortality (HR: 0.450; 95% CI: 0.218–0.926, $p = 0.030$ )
Faroux <i>et al.</i> 2020 [88],	Multicentre retrospective registry	TAVI + PCI in both groups: - 889 CR - 308 IR	2 years	MACCE	CR = lower MACCE (HR: 0.77; 95% CI: 0.63–0.95, $p = 0.014$ )
Minten <i>et al.</i> 2022 [16]	Single centre prospective study	TAVI + PCI in all groups: - 66 RCR (rSS = 1–7) - 41 IR (rSS ≥8)	5 years	All-cause mortality Cardiovascular mortality	No difference ( $p = 0.678$ ) No difference ( $p = 0.361$ )
Costa <i>et al.</i> 2022 [94]	Multi-centre retrospective registry	Stable CAD in TAVI: - 657 CR - 287 IR - 370 no revascularisation	2 years	Cardiovascular death MACCE	No difference ( $p = 0.63$ ) No difference ( $p = 0.94$ )

CAD, coronary artery disease; 95% CI, 95% confidence interval; CR, complete revascularization; HR, hazard ratio; IR, incomplete revascularization; LM, left mainstem coronary artery; MACCE, major adverse cardiac and cerebrovascular events; PCI, Percutaneous coronary intervention; rSS, residual Syntax score; SS, Syntax-score; TAVI, Transcatheter aortic valve implantation.

**Table 3. Future and ongoing studies on CAD physiological assessment and treatment in TAVR patients.**

Study	Design	Population	Recruitment target	Description	Primary outcome	Completion date
<b>FORTUNA</b> [110] (NCT03665389)	Single centre, prospective open-label study	TAVI patients with moderate-severe CAD	25	CT-based FFR, FFR and iFR pre-TAVR and FFR and iFR post-TAVR	Comparison between CT based FFR and iFR/FFR	2023
<b>FAVOR IV-QVAS</b> [111] (NCT03977129)	Multicentre, randomized control trial	AS patients undergoing valve surgery + moderate to severe CAD	792	Angiography guides vs QFR guided revascularization	Composite endpoint: all-cause mortality, MI, stroke, unplanned revascularization, kidney injury requiring dialysis at 30 days	2026
<b>COMIC-AS</b> [62] (NCT04420325)	Multicentre, prospective cohort study	AS patients undergoing TAVI or SAVR + moderate to severe CAD	100	FFR, RFR, CFR and IMR with SPECT myocardial perfusion imaging pre-(T)AVR and FFR, RFR, CFR and IMR immediately and 6 months after TAVI	Change in FFR and RFR, correlation between indices and non-invasive imaging at 6 months	2024
<b>TCW</b> [112] (NCT03424941)	Multicentre, open-label, non-inferiority randomized controlled trial	AS patients undergoing SAVR/TAVI with multivesel CAD	328	CABG + SAVR vs FFR-guided PCI +TAVI	Composite endpoint: mortality, MI, disabling stroke, major bleeding, valve re-intervention or need for target lesion revascularization at 1 year	2024
<b>FAITAVI</b> [113] (NCT03360591)	Single centre, open-label, randomized controlled trial	AS patients undergoing TAVI with moderate to severe CAD	320	Angiography guided versus physiology guided PCI	Composite endpoint: all-cause mortality, MI, stroke, major bleeding and target lesions revascularization at 1 year	2024
<b>NOTION-3</b> [114] (NCT03058627)	Multicentre, open-label, randomized controlled trial	AS patients undergoing TAVI, with one significant coronary lesion (FFR $\leq$ 0.80 or $>$ 90% diameter stenosis)	452	TAVI + FFR-guided complete revascularization vs TAVI + medical management of CAD	Composite endpoint: all cause death, myocardial infarction, or urgent revascularization at 1 year	2027
<b>TAVI-PCI</b> [115] (NCT04310046)	Open-label, randomized controlled trial	AS patients undergoing TAVI and PCI for CAD	986	iFR-guided revascularization: performed 1–45 days before versus 1–45 days after TAVI	Composite endpoint: All-cause mortality, MI; ischemia driven revascularization, rehospitalization, major bleeding at 1 year	2028

CABG, Coronary Artery Bypass Grafting; CAD, coronary artery disease; CFR, coronary flow reserve; CT, computed tomography; FFR, fractional flow reserve; iFR, instantaneous wave-free ratio; IMR, index of microvascular resistance; MI, myocardial infarction; QFR, Quantitative flow ratio; RFR, resting full-cycle ratio; SAVR, surgical aortic valve replacement; SPECT, Single photon-emission computed tomography; TAVI, transcatheter aortic valve implantation.



Performing PCI before TAVI has the theoretical disadvantage of inflicting multiple hospital admissions and invasive cardiovascular procedures to the patient with repeated risk for contrast induced kidney injury, while increasing dual antiplatelet-related bleeding risk following TAVI. The benefits of this strategy include the potential reduction of ischemia during TAVI, in case of severe lesions with high-risk features or left main stem disease, especially when rapid pacing is required [98]. Moreover, the PCI-first strategy will maintain optimal coronary access, allowing optimal guide catheter support for more complex revascularization. It remains unclear, however, how long the time interval between PCI and TAVI should be. One study showed that there was no significant difference in mortality at 2 year follow-up between PCI within one month or more than one month prior to TAVI [99]. Nevertheless, the group with the PCI closer to the valve procedure had significantly more bleeding and minor vascular complications, suggesting a potential benefit of leaving enough time between both procedures.

Performing PCI and TAVI in one procedure is feasible and limits the number of hospital admissions and invasive cardiovascular procedures [100,101]. However, the higher volume of contrast medium administered in these combined interventions carries an increased risk for acute kidney injury, especially when considering complex CAD interventions in frail patients. Furthermore, the results of a large registry suggest that patients undergoing PCI during the same admission as TAVI had a higher rate of complications and mortality [102].

There is general agreement that overall, in patients with severe AS and CAD, the severity of the valve disorder is driving the symptoms and risk, and PCI should only be considered for severe proximal lesions in vessels supplying a large myocardial territory [9]. Deferring PCI until after TAVI, to observe how symptoms (and coronary indices such as FFR and RFR) evolve, seems like a valid strategy, especially in equivocal lesions [103]. This is supported by previously mentioned studies showing no short-term outcome benefit of PCI. Moreover, although patients with complex (CAD) had worse outcomes in a recent study, this difference only started to appear after a few years [16]. TAVI operators should however take into account the impact of the valve procedure on future coronary access as in some cases access may become technically challenging depending on the anatomy of the aortic root and the valve type used [104]. While it has been reported that PCI after TAVI has a high success rate for all available transcatheter valves [105,106], modifications in PCI and TAVI technique are sometimes necessary [107,108]. In this respect, the use of the Evolut R/PRO valve, the interaction of the valve with the sinus of Valsalva and the mean valve implantation depth have been identified as independent predictors for difficult coronary access post-TAVI [109].

## 5. Future Perspectives

The challenge remains to identify which patients and coronary lesions may benefit from myocardial revascularization at the time of AVR in the setting of severe AS. While non-invasive functional imaging, such as CT-based FFR looks promising, its potential role, even in a context without AS, needs to be finetuned. However, invasive assessment of coronary physiology by means of FFR and non-hyperemic pressure ratios (NHPRs) has become standard practice in cathlabs, and decision algorithms for revascularization should now be validated or adapted in the context of AS. Currently, several smaller or larger scale studies are recruiting patients in this field, focusing on either mechanistic understanding of physiologic variables impacted by AS, or rather pure clinical outcomes (Table 3, Ref. [62,110–115]). Ultimately, randomized controlled trials, will be needed to answer remaining questions. As a matter of fact, the COMPLETE TAVR trial (NCT04634240) is comparing medical therapy versus complete revascularization in patients undergoing TAVI. The TAVI-PCI (NCT04310046) study is trying to determine the ideal timing for physiology-guided revascularization relative to the TAVI. Further studies regarding gender differences in regard to CAD in patients undergoing TAVI will also be important [116].

## 6. Conclusions

Patients with CAD and severe AS represent a frequently-encountered clinical entity in daily practice. It appears that (complex) CAD independently negatively influences the outcomes after AVR and so deserves particular attention. Although important, the ideal methods to assess and treat CAD in this population remain unclear. Some data suggest complete revascularization might benefit these patients but many studies fail to show a beneficial effect of angiography-guided PCI in this population. Severe AS induces severe coronary hemodynamic changes that make the physiological assessment of lesions severity challenging. Nevertheless, this field is advancing rapidly and several large clinical trials are actively recruiting and will significantly improve our understanding of CAD in the setting of severe AS.

## Author Contributions

LM, JB, KM and CD participated in conceptualization and methodology of the review article. LM performed the data gathering, analysis and wrote the first draft. CD, JB, KM reviewed and edited the first draft. LM Finalized the final draft and made the figures and tables. CD and JB supervised the review article. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.

## Ethics Approval and Consent to Participate

Not applicable.

## Acknowledgment

Not applicable.

## Funding

L. Minten is supported by the Research Foundation Flanders Grant 1194521 N and Belgian Fund For Heart surgery Grant 489686.

## Conflict of Interest

The authors declare no conflict of interest.

## References

- [1] Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. *Journal of the American College of Cardiology*. 2012; 60: 1854–1863.
- [2] Akins CW, Daggett WM, Vlahakes GJ, Hilgenberg AD, Torchiana DF, Madsen JC, *et al*. Cardiac operations in patients 80 years old and older. *The Annals of Thoracic Surgery*. 1997; 64: 606–615.
- [3] Kvidal P, Bergström R, Hörte LG, Ståhle E. Observed and relative survival after aortic valve replacement. *Journal of the American College of Cardiology*. 2000; 35: 747–756.
- [4] Walther T, Hamm CW, Schuler G, Berkowitsch A, Kötting J, Mangner N, *et al*. Perioperative Results and Complications in 15,964 Transcatheter Aortic Valve Replacements: Prospective Data From the GARY Registry. *Journal of the American College of Cardiology*. 2015; 65: 2173–2180.
- [5] Kotronias RA, Kwok CS, George S, Capodanno D, Ludman PF, Townend JN, *et al*. Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis. *Journal of the American Heart Association*. 2017; 6: e005960.
- [6] D’Ascenzo F, Verardi R, Visconti M, Conrotto F, Scacciarella P, Dziewierz A, *et al*. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. *EuroIntervention*. 2018; 14: e1169–e1177.
- [7] Rapp AH, Hillis LD, Lange RA, Cigarroa JE. Prevalence of coronary artery disease in patients with aortic stenosis with and without angina pectoris. *The American Journal of Cardiology*. 2001; 87: 1216–7; A7.
- [8] Julius BK, Spillmann M, Vassalli G, Villari B, Eberli FR, Hess OM. Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts. *Circulation*. 1997; 95: 892–898.
- [9] Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, *et al*. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2021; 77: e25–e197.
- [10] Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, *et al*. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *European Heart Journal*. 2022; 43: 561–632.
- [11] Pijls NH, De Bruyne B, Peels K, Van Der Voort PH, Bonnier HJ, Bartunek J, Koolen JJ, *et al*. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. *The New England Journal of Medicine*. 1996; 334: 1703–1708.
- [12] Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van’t Veer M, *et al*. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *The New England Journal of Medicine*. 2009; 360: 213–224.
- [13] Tjang YS, van Hees Y, Körfer R, Grobbee DE, van der Heijden GJMG. Predictors of mortality after aortic valve replacement. *European Journal of Cardio-thoracic Surgery*. 2007; 32: 469–474.
- [14] Lund O, Nielsen TT, Pilegaard HK, Magnussen K, Knudsen MA. The influence of coronary artery disease and bypass grafting on early and late survival after valve replacement for aortic stenosis. *The Journal of Thoracic and Cardiovascular Surgery*. 1990; 100: 327–337.
- [15] Sankaramangalam K, Banerjee K, Kandregula K, Mohananeey D, Parashar A, Jones BM, *et al*. Impact of Coronary Artery Disease on 30-Day and 1-Year Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis. *Journal of the American Heart Association*. 2017; 6: e006092.
- [16] Minten L, Wissels P, McCutcheon K, Bennett J, Adriaenssens T, Desmet W, *et al*. The Effect of Coronary Lesion Complexity and Preprocedural Revascularization on 5-Year Outcomes After TAVR. *JACC: Cardiovascular Interventions*. 2022; 15: 1611–1620.
- [17] Singh A, Greenwood JP, Berry C, Dawson DK, Hogrefe K, Kelly DJ, *et al*. Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. *European Heart Journal*. 2017; 38: 1222–1229.
- [18] Darty S. Safety of adenosine stress perfusion cardiac magnetic resonance imaging in patients with aortic stenosis. *Journal of Cardiovascular Magnetic Resonance*. 2011; 13: O38.
- [19] Cremer PC, Khalaf S, Lou J, Rodriguez L, Cerqueira MD, Jaber WA. Stress positron emission tomography is safe and can guide coronary revascularization in high-risk patients being considered for transcatheter aortic valve replacement. *Journal of Nuclear Cardiology*. 2014; 21: 1001–1010.
- [20] Patsilinos SP, Kranidis AI, Antonelis IP, Filippatos G, Housianakou IK, Zamanis NI, *et al*. Detection of coronary artery disease in patients with severe aortic stenosis with noninvasive methods. *Angiology*. 1999; 50: 309–317.
- [21] Demirkol MO, Yaymaci B, Debeş H, Başaran Y, Turan F. Dipyridamole myocardial perfusion tomography in patients with severe aortic stenosis. *Cardiology*. 2002; 97: 37–42.
- [22] Patsilinos SP, Spanodimos S, Rontoyanni F, Kranidis A, Antonelis IP, Sotirellos K, *et al*. Adenosine stress myocardial perfusion tomographic imaging in patients with significant aortic stenosis. *Journal of Nuclear Cardiology*. 2004; 11: 20–25.
- [23] Hussain N, Chaudhry W, Ahlberg AW, Amara RS, Elfar A, Parker MW, *et al*. An assessment of the safety, hemodynamic response, and diagnostic accuracy of commonly used vasodilator stressors in patients with severe aortic stenosis. *Journal of Nuclear Cardiology*. 2017; 24: 1200–1213.
- [24] Samuels B, Kiat H, Friedman JD, Berman DS. Adenosine pharmacologic stress myocardial perfusion tomographic imaging in patients with significant aortic stenosis. Diagnostic efficacy and comparison of clinical, hemodynamic and electrocardiographic variables with 100 age-matched control subjects. *Journal of the American College of Cardiology*. 1995; 25: 99–106.
- [25] Yamanaka F, Shishido K, Ochiai T, Moriyama N, Yamazaki K, Sugitani A, *et al*. Instantaneous Wave-Free Ratio for the Assessment of Intermediate Coronary Artery Stenosis in Patients With Severe Aortic Valve Stenosis: Comparison With Myocardial Perfusion Scintigraphy. *JACC: Cardiovascular Interventions*. 2018; 11: 2032–2040.
- [26] Scarsini R, Cantone R, Venturi G, De Maria GL, Variola A, Braggio P, *et al*. Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic

- stenosis. *International Journal of Cardiology*. 2019; 292: 162–165.
- [27] Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, *et al*. Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. *Circulation: Cardiovascular Interventions*. 2015; 8: e002025.
- [28] Rossi A, De Cecco CN, Kennon SRO, Zou L, Meinel FG, Toscano W, *et al*. CT angiography to evaluate coronary artery disease and revascularization requirement before transcatheter aortic valve replacement. *Journal of Cardiovascular Computed Tomography*. 2017; 11: 338–346.
- [29] Matsumoto S, Yamada Y, Hashimoto M, Okamura T, Yamada M, Yashima F, *et al*. CT imaging before transcatheter aortic valve implantation (TAVI) using variable helical pitch scanning and its diagnostic performance for coronary artery disease. *European Radiology*. 2017; 27: 1963–1970.
- [30] Opolski MP, Kim W, Liebetrau C, Walther C, Blumenstein J, Gaede L, *et al*. Diagnostic accuracy of computed tomography angiography for the detection of coronary artery disease in patients referred for transcatheter aortic valve implantation. *Clinical Research in Cardiology*. 2015; 104: 471–480.
- [31] Harris BS, De Cecco CN, Schoepf UJ, Steinberg DH, Bayer RR, Krazinski AW, *et al*. Dual-source CT imaging to plan transcatheter aortic valve replacement: accuracy for diagnosis of obstructive coronary artery disease. *Radiology*. 2015; 275: 80–88.
- [32] Hamdan A, Wellnhofer E, Konen E, Kelle S, Goitein O, Andrada B, *et al*. Coronary CT angiography for the detection of coronary artery stenosis in patients referred for transcatheter aortic valve replacement. *Journal of Cardiovascular Computed Tomography*. 2015; 9: 31–41.
- [33] Andreini D, Pontone G, Mushtaq S, Bartorelli AL, Ballerini G, Bertella E, *et al*. Diagnostic accuracy of multidetector computed tomography coronary angiography in 325 consecutive patients referred for transcatheter aortic valve replacement. *American Heart Journal*. 2014; 168: 332–339.
- [34] Pontone G, Andreini D, Bartorelli AL, Annoni A, Mushtaq S, Bertella E, *et al*. Feasibility and accuracy of a comprehensive multidetector computed tomography acquisition for patients referred for balloon-expandable transcatheter aortic valve implantation. *American Heart Journal*. 2011; 161: 1106–1113.
- [35] Yang L, Zhou T, Zhang R, Xu L, Peng Z, Ding J, *et al*. Meta-analysis: diagnostic accuracy of coronary CT angiography with prospective ECG gating based on step-and-shoot, Flash and volume modes for detection of coronary artery disease. *European Radiology*. 2014; 24: 2345–2352.
- [36] van den Boogert TPW, Vendrik J, Claessen BEPM, Baan J, Beijik MA, Limpens J, *et al*. CTCA for detection of significant coronary artery disease in routine TAVI work-up: A systematic review and meta-analysis. *Netherlands Heart Journal*. 2018; 26: 591–599.
- [37] Michail M, Ihdahid A, Comella A, Thakur U, Cameron JD, McCormick LM, *et al*. Feasibility and Validity of Computed Tomography-Derived Fractional Flow Reserve in Patients With Severe Aortic Stenosis: The CAST-FFR Study. *Circulation: Cardiovascular Interventions*. 2021; 14: e009586.
- [38] Van Mieghem NM, van der Boon RM, Faqiri E, Diletti R, Schultz C, van Geuns R, *et al*. Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. *JACC: Cardiovascular Interventions*. 2013; 6: 867–875.
- [39] Pasic M, Dreyse S, Unbehaun A, Buz S, Drews T, Klein C, *et al*. Combined elective percutaneous coronary intervention and transapical transcatheter aortic valve implantation. *Interactive Cardiovascular and Thoracic Surgery*. 2012; 14: 463–468.
- [40] Gasparetto V, Fraccaro C, Tarantini G, Buja P, D’Onofrio A, Yzeiraj E, *et al*. Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation. *Catheterization and Cardiovascular Interventions*. 2013; 81: 376–383.
- [41] Abdel-Wahab M, Mostafa AE, Geist V, Stöcker B, Gordian K, Merten C, *et al*. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation versus combined with preprocedural percutaneous coronary intervention. *The American Journal of Cardiology*. 2012; 109: 581–586.
- [42] Gautier M, Pepin M, Himbert D, Ducrocq G, Jung B, Dilly M, *et al*. Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. *EuroIntervention*. 2011; 7: 549–555.
- [43] Abramowitz Y, Banai S, Katz G, Steinvil A, Arbel Y, Havakuk O, *et al*. Comparison of early and late outcomes of TAVI alone compared to TAVI plus PCI in aortic stenosis patients with and without coronary artery disease. *Catheterization and Cardiovascular Interventions*. 2014; 83: 649–654.
- [44] Khawaja MZ, Asrress KN, Haran H, Arri S, Nadra I, Bolter K, *et al*. The effect of coronary artery disease defined by quantitative coronary angiography and SYNTAX score upon outcome after transcatheter aortic valve implantation (TAVI) using the Edwards bioprosthesis. *EuroIntervention*. 2015; 11: 450–455.
- [45] Villari B, Hess OM, Meier C, Pucillo A, Gaglione A, Turina M, *et al*. Regression of coronary artery dimensions after successful aortic valve replacement. *Circulation*. 1992; 85: 972–978.
- [46] Tu S, Xu L, Ligthart J, Xu B, Witberg K, Sun Z, *et al*. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography. *The International Journal of Cardiovascular Imaging*. 2012; 28: 1315–1327.
- [47] Mejia-Rentería H, Nombela-Franco L, Paradis J, Lunardi M, Lee JM, Amat-Santos IJ, *et al*. Angiography-based quantitative flow ratio versus fractional flow reserve in patients with coronary artery disease and severe aortic stenosis. *EuroIntervention*. 2020; 16: e285–e292.
- [48] Minten L, McCutcheon K, Bennett J, Dubois C. Coronary physiology to guide treatment of coronary artery disease in a patient with severe aortic valve stenosis: friend or foe? A case report. *European Heart Journal. Case Reports*. 2022; 6: ytac333.
- [49] Jasti V, Ivan E, Yalamançhili V, Wongpraparut N, Leesar MA. Correlations between fractional flow reserve and intravascular ultrasound in patients with an ambiguous left main coronary artery stenosis. *Circulation*. 2004; 110: 2831–2836.
- [50] de la Torre Hernandez JM, Hernández Hernandez F, Alfonso F, Rumoroso JR, Lopez-Palop R, Sadaba M, *et al*. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. *Journal of the American College of Cardiology*. 2011; 58: 351–358.
- [51] Kang S, Lee J, Ahn J, Mintz GS, Kim W, Park D, *et al*. Validation of intravascular ultrasound-derived parameters with fractional flow reserve for assessment of coronary stenosis severity. *Circulation: Cardiovascular Interventions*. 2011; 4: 65–71.
- [52] Park S, Ahn J, Kang S, Yoon S, Koo B, Lee J, *et al*. Intravascular ultrasound-derived minimal lumen area criteria for functionally significant left main coronary artery stenosis. *JACC: Cardiovascular Interventions*. 2014; 7: 868–874.
- [53] Masson J, Lee M, Boone RH, Al Ali A, Al Bugami S, Hamburger J, *et al*. Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. *Catheterization and Cardiovascular Interventions*. 2010; 76: 165–173.
- [54] Sianos G, Morel M, Kappetein AP, Morice M, Colombo A, Dawkins K, *et al*. The SYNTAX Score: an angiographic tool

- grading the complexity of coronary artery disease. *EuroIntervention*. 2005; 1: 219–227.
- [55] O’Sullivan CJ, Englberger L, Hosek N, Heg D, Cao D, Stefanini GG, *et al.* Clinical outcomes and revascularization strategies in patients with low-flow, low-gradient severe aortic valve stenosis according to the assigned treatment modality. *JACC: Cardiovascular Interventions*. 2015; 8: 704–717.
- [56] Brosh D, Higano ST, Lennon RJ, Holmes DR, Lerman A. Effect of lesion length on fractional flow reserve in intermediate coronary lesions. *American Heart Journal*. 2005; 150: 338–343.
- [57] De Bruyne B, Fearon WF, Pijls NHJ, Barbato E, Tonino P, Piroth Z, *et al.* Fractional flow reserve-guided PCI for stable coronary artery disease. *The New England Journal of Medicine*. 2014; 371: 1208–1217.
- [58] De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, *et al.* Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. *The New England Journal of Medicine*. 2012; 367: 991–1001.
- [59] Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, *et al.* 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Journal of the American College of Cardiology*. 2014; 64: 1929–1949.
- [60] Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, *et al.* 2018 ESC/EACTS Guidelines on myocardial revascularization. *European Heart Journal*. 2019; 40: 87–165.
- [61] Lunardi M, Scarsini R, Venturi G, Pesarini G, Pighi M, Gratta A, *et al.* Physiological Versus Angiographic Guidance for Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation. *Journal of the American Heart Association*. 2019; 8: e012618.
- [62] Minten L, McCutcheon K, Jentjens S, Vanhaverbeke M, Segers VFM, Bennett J, *et al.* The coronary and microcirculatory measurements in patients with aortic valve stenosis study: rationale and design. *American Journal of Physiology. Heart and Circulatory Physiology*. 2021; 321: H1106–H1116.
- [63] Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, *et al.* Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. *Journal of the American College of Cardiology*. 2013; 61: 837–848.
- [64] Roberts WC, Roberts CC, Vowels TJ, Ko JM, Filardo G, Hamman BL, *et al.* Effect of coronary bypass and valve structure on outcome in isolated valve replacement for aortic stenosis. *The American Journal of Cardiology*. 2012; 109: 1334–1340.
- [65] Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, *et al.* The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era. *The Journal of Thoracic and Cardiovascular Surgery*. 2015; 149: 451–460.
- [66] Santana O, Funk M, Zamora C, Escolar E, Lamas GA, Lameelas J. Staged percutaneous coronary intervention and minimally invasive valve surgery: results of a hybrid approach to concomitant coronary and valvular disease. *The Journal of Thoracic and Cardiovascular Surgery*. 2012; 144: 634–639.
- [67] Byrne JG, Leacche M, Unic D, Rawn JD, Simon DI, Rogers CD, *et al.* Staged initial percutaneous coronary intervention followed by valve surgery (“hybrid approach”) for patients with complex coronary and valve disease. *Journal of the American College of Cardiology*. 2005; 45: 14–18.
- [68] Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, *et al.* Optimal medical therapy with or without PCI for stable coronary disease. *The New England Journal of Medicine*. 2007; 356: 1503–1516.
- [69] Al-Lamee R, Thompson D, Dehbi H, Sen S, Tang K, Davies J, *et al.* Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *Lancet*. 2018; 391: 31–40.
- [70] Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, *et al.* Initial Invasive or Conservative Strategy for Stable Coronary Disease. *The New England Journal of Medicine*. 2020; 382: 1395–1407.
- [71] Koskinas KC, Stortecky S, Franzone A, O’Sullivan CJ, Praz F, Zuk K, *et al.* Post-Procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation. *Journal of the American Heart Association*. 2016; 5: e002430.
- [72] Sinning J, Hammerstingl C, Schueler R, Neugebauer A, Keul S, Ghanem A, *et al.* The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation. *EuroIntervention*. 2016; 11: 1522–1529.
- [73] Wenaweser P, Pilgrim T, Guerios E, Stortecky S, Huber C, Khatatba AA, *et al.* Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. *EuroIntervention*. 2011; 7: 541–548.
- [74] Codner P, Assali A, Dvir D, Vaknin-Assa H, Porat E, Shapira Y, *et al.* Two-year outcomes for patients with severe symptomatic aortic stenosis treated with transcatheter aortic valve implantation. *The American Journal of Cardiology*. 2013; 111: 1330–1336.
- [75] Snow TM, Ludman P, Banya W, DeBelder M, MacCarthy PM, Davies SW, *et al.* Management of concomitant coronary artery disease in patients undergoing transcatheter aortic valve implantation: the United Kingdom TAVI Registry. *International Journal of Cardiology*. 2015; 199: 253–260.
- [76] Huczek Z, Zbroński K, Grodecki K, Scisło P, Rymuza B, Kochman J, *et al.* Concomitant coronary artery disease and its management in patients referred to transcatheter aortic valve implantation: Insights from the POL-TAVI Registry. *Catheterization and Cardiovascular Interventions*. 2018; 91: 115–123.
- [77] Chakravarty T, Sharma R, Abramowitz Y, Kapadia S, Latib A, Jilaihawi H, *et al.* Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM Registry. *Journal of the American College of Cardiology*. 2016; 67: 951–960.
- [78] Millan-Iturbe O, Sawaya FJ, Lønborg J, Chow DHF, Bieliauskas G, Engstrøm T, *et al.* Coronary artery disease, revascularization, and clinical outcomes in transcatheter aortic valve replacement: Real-world results from the East Denmark Heart Registry. *Catheterization and Cardiovascular Interventions*. 2018; 92: 818–826.
- [79] Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, *et al.* Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *The New England Journal of Medicine*. 2016; 374: 1609–1620.
- [80] Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, *et al.* Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *The New England Journal of Medicine*. 2017; 376: 1321–1331.
- [81] Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, *et al.* Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *The New England Journal of Medicine*. 2019; 380: 1706–1715.
- [82] Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, *et al.* Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *The New England Journal of Medicine*. 2019; 380: 1695–1705.
- [83] Stefanini GG, Stortecky S, Cao D, Rat-Wirtzler J, O’Sullivan

- CJ, Gloekler S, *et al.* Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. *European Heart Journal*. 2014; 35: 2530–2540.
- [84] Kleczynski P, Dziewierz A, Bagiński M, Rzeszutko L, Sorysz D, Trebacz J, *et al.* Impact of Coronary Artery Disease Burden on 12-Month Mortality of Patients After Transcatheter Aortic Valve Implantation. *Journal of Interventional Cardiology*. 2016; 29: 375–381.
- [85] Shamekhi J, Stundl A, Weber M, Mellert F, Welz A, Grube E, *et al.* Impact of coronary artery disease in patients undergoing transfemoral transcatheter aortic valve implantation. *International Journal of Cardiology*. 2017; 245: 215–221.
- [86] Witberg G, Regev E, Chen S, Assali A, Barbash IM, Planer D, *et al.* The Prognostic Effects of Coronary Disease Severity and Completeness of Revascularization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. *JACC: Cardiovascular Interventions*. 2017; 10: 1428–1435.
- [87] Landt M, Abdelghani M, Hemetsberger R, Mankerious N, Allali A, Toelg R, *et al.* Impact of Revascularization Completeness on Outcomes of Patients with Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement. *Structural Heart*. 2019; 3: 393–400.
- [88] Faroux L, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Fischer Q, Donaint P, *et al.* Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR. *JACC: Cardiovascular Interventions*. 2020; 13: 2601–2613.
- [89] Ussia GP, Barbanti M, Colombo A, Tarantini G, Petronio AS, Ettore F, *et al.* Impact of coronary artery disease in elderly patients undergoing transcatheter aortic valve implantation: insight from the Italian CoreValve Registry. *International Journal of Cardiology*. 2013; 167: 943–950.
- [90] Paradis J, White JM, Généreux P, Urena M, Doshi D, Nazif T, *et al.* Impact of Coronary Artery Disease Severity Assessed With the SYNTAX Score on Outcomes Following Transcatheter Aortic Valve Replacement. *Journal of the American Heart Association*. 2017; 6: e005070.
- [91] Li J, Patel SM, Nadeem F, Thakker P, Al-Kindi S, Thomas R, *et al.* Impact of residual coronary atherosclerosis on transfemoral transcatheter aortic valve replacement. *Catheterization and Cardiovascular Interventions*. 2019; 93: 545–552.
- [92] López Otero D, Ávila-Carrillo A, González Ferreiro R, Cid Menéndez A, Iglesias Álvarez D, Álvarez Rodríguez L, *et al.* Impact of Coronary Revascularization in Patients Who Underwent Transcatheter Aortic Valve Implantation. *The American Journal of Cardiology*. 2019; 123: 948–955.
- [93] Saia F, Palmerini T, Compagnone M, Battistini P, Moretti C, Taglieri N, *et al.* Coronary artery disease and reasonably incomplete coronary revascularization in high-risk patients undergoing transcatheter aortic valve implantation. *Catheterization and Cardiovascular Interventions*. 2020; 95: 19–27.
- [94] Costa G, Pilgrim T, Amat Santos IJ, De Backer O, Kim W, Barbosa Ribeiro H, *et al.* Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation. *Circulation: Cardiovascular Interventions*. 2022; 15: e012417.
- [95] Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, *et al.* ACTIVATION (Percutaneous Coronary Intervention prior to transcatheter aortic Valve implantation): A Randomized Clinical Trial. *JACC: Cardiovascular Interventions*. 2021; 14: 1965–1974.
- [96] Sabbah M, Olsen NT, Holmvang L, Tilsted H, Pedersen F, Joshi FR, *et al.* Long-term changes in coronary physiology after aortic valve replacement. *EuroIntervention*. 2022. (online ahead of print)
- [97] Patel K, Broyd C, Chehab O, Jerrum M, Queenan H, Bedford K, *et al.* Transcatheter aortic valve implantation in acute decompensated aortic stenosis. *Catheterization and Cardiovascular Interventions*. 2020; 96: E348–E354.
- [98] Fefer P, Bogdan A, Grossman Y, Berkovitch A, Brodov Y, Kupstein R, *et al.* Impact of Rapid Ventricular Pacing on Outcome After Transcatheter Aortic Valve Replacement. *Journal of the American Heart Association*. 2018; 7: e009038.
- [99] van Rosendaal PJ, van der Kley F, Kamperidis V, Katsanos S, Al Amri I, Regeer M, *et al.* Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation. *The American Journal of Cardiology*. 2015; 115: 1726–1732.
- [100] Penkalla A, Pasic M, Drews T, Buz S, Dreyse S, Kukucka M, *et al.* Transcatheter aortic valve implantation combined with elective coronary artery stenting: a simultaneous approach. *European Journal of Cardio-Thoracic Surgery*. 2015; 47: 1083–1089.
- [101] Barbanti M, Todaro D, Costa G, Pilato G, Picci A, Gulino S, *et al.* Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. *Circulation: Cardiovascular Interventions*. 2017; 10: e005234.
- [102] Singh V, Rodriguez AP, Thakkar B, Patel NJ, Ghatak A, Badheka AO, *et al.* Comparison of Outcomes of Transcatheter Aortic Valve Replacement Plus Percutaneous Coronary Intervention Versus Transcatheter Aortic Valve Replacement Alone in the United States. *The American Journal of Cardiology*. 2016; 118: 1698–1704.
- [103] Minten L, Bennett J, Dubois C. Reply: Percutaneous Coronary Revascularization in Patients Undergoing TAVR: A Different Entity or More of the Same? *JACC: Cardiovascular Interventions*. 2022; 15: 2348–2349.
- [104] Valvo R, Costa G, Tamburino C, Barbanti M. Coronary artery cannulation after transcatheter aortic valve implantation. *EuroIntervention*. 2021; 17: 835–847.
- [105] Stefanini GG, Cerrato E, Pivato CA, Joner M, Testa L, Rheude T, *et al.* Unplanned Percutaneous Coronary Revascularization After TAVR: A Multicenter International Registry. *JACC: Cardiovascular Interventions*. 2021; 14: 198–207.
- [106] Nai Fovino L, Scotti A, Massussi M, Fabris T, Cardaioli F, Rodinò G, *et al.* Incidence and feasibility of coronary access after transcatheter aortic valve replacement. *Catheterization and Cardiovascular Interventions*. 2020; 96: E535–E541.
- [107] Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary Angiography and Percutaneous Coronary Intervention After Transcatheter Aortic Valve Replacement. *Journal of the American College of Cardiology*. 2018; 71: 1360–1378.
- [108] Khan M, Senguttuvan NB, Krishnamoorthy P, Vengrenyuk Y, Tang GHL, Sharma SK, *et al.* Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement with medtronic self-expanding prosthesis: Insights from correlations with computer tomography. *International Journal of Cardiology*. 2020; 317: 18–24.
- [109] Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, *et al.* Coronary Cannulation After Transcatheter Aortic Valve Replacement: The RE-ACCESS Study. *JACC: Cardiovascular Interventions*. 2020; 13: 2542–2555.
- [110] Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography in Patients Undergoing TAVR (FORTUNA). 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT03665389> (Accessed: 2 January 2023).
- [111] Quantitative Flow Ratio (QFR) Guided Revascularization Strategy for Patients Undergoing Primary Valve Surgery With Comorbid Coronary Artery Disease (FAVOR4-QVAS). 2019. Available at: <https://clinicaltrials.gov/ct2/show/NCT03977129> (Accessed: 2 January 2023).

- [112] The TransCatheter Valve and Vessels Trial (TCW). 2018. Available at: <https://clinicaltrials.gov/ct2/show/NCT03424941> (Accessed: 2 January 2023).
- [113] Functional Assessment In TAVI: FAITAVI (FAITAVI). 2017. Available at: <https://clinicaltrials.gov/ct2/show/NCT03360591> (Accessed: 2 January 2023).
- [114] Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation (NOTION-3). 2017. Available at: <https://clinicaltrials.gov/ct2/show/NCT03058627> (Accessed: 2 January 2023).
- [115] Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial (TAVI-PCI). 2020. Available at: <https://clinicaltrials.gov/ct2/show/NCT04310046> (Accessed: 2 January 2023).
- [116] Minten L, Bennett J, Wissels P, McCutcheon K, Dubois C. Gender Differences in the Impact of Coronary Artery Disease and Complete Revascularization on Long-Term Outcomes After Transcatheter Aortic Valve Implantation. *The American Journal of Cardiology*. 2023; 191: 133–135.